

Supplementary Appendix 4. The details of comorbidities of the included patients in the meta-analysis

No.	Author (year)	Hypertension, %	Diabetes mellitus, %	Cardiovascular comorbidities, %	Pulmonary comorbidities, %	Cerebrovascular disease, %	Chronic liver disease, %	Chronic kidney disease, %	Cancer, %
1	Ashraf MA. (2020)	26.0	26.0	19.0	13.0	-	-	-	-
2	Bean D. (2020)	Total: 51.2, ACEI/ARB group: 82.6 Non-ACEI/ARB group: 42.1	Total: 30.2 ACEI/ARB group: 50.0 Non-ACEI/ARB group: 24.5	Total: 14.6 ACEI/ARB group: 28.3 Non-ACEI/ARB group: 10.7	-	-	-	-	-
3	Benelli G. (2020)	47.0	16.3	22.6	11.7	-	-	5.3	8.0
4	Caraballo C. (2020)	79.6	-	35.4	32.5	-	-	38.3	-
5	Feng Y (2020)	100 (23.7)	(10.3) ^a	(8.0) ^a	(4.6) ^a	(3.6) ^a	-	(0.8) ^a	(2.5) ^a
6	Feng Z. (2020) ^a	100 (14.5)	Total: 30.8 (8.0), ACEI/ARB group: 12.5, Non-ACEI/ARB group: 36.7	Total: 12.3 (3.9), ACEI/ARB group: 0, Non-ACEI/ARB group: 16.3	Total: 1.5 (21.3), ACEI/ARB group: 0, Non-ACEI/ARB group: 2.0	Total: 4.6 (0.9), ACEI/ARB group: 0, Non-ACEI/ARB group: 6.1	Total: 3.1 (1.6), ACEI/ARB group: 0, Non-ACEI/ARB group: 4.1	Total: 3.1 (0.5), ACEI/ARB group: 6.3, Non-ACEI/ARB group: 2.0	-
7	Ip A. (2020)	100	-	-	-	-	-	-	-
8	Lee H. (2020)	ACEI/ARB group: 97.3 Non-ACEI/ARB group: 8.6	ACEI/ARB group: 50.0 Non-ACEI/ARB group: 12.6	ACEI/ARB group: 19.7 Non-ACEI/ARB group: 3.8	ACEI/ARB group: 25.7 Non-ACEI/ARB group: 12.8	ACEI/ARB group: 12.3 Non-ACEI/ARB group: 1.6	-	ACEI/ARB group: 4.3 Non-ACEI/ARB group: 0.6	ACEI/ARB group: 9.0 Non-ACEI/ARB group: 0.6
9	Li J. (2020)	100	ACEI/ARB group: 36.5 Non-ACEI/ARB group: 34.4	ACEI/ARB group: 23.5 Non-ACEI/ARB group: 14.2	ACEI/ARB group: 7.0 Non-ACEI/ARB group: 4.0	ACEI/ARB group: 23.5 Non-ACEI/ARB group: 16.6	-	ACEI/ARB group: 11.3 Non-ACEI/ARB group: 8.9	ACEI/ARB group: 1.7 Non-ACEI/ARB group: 3.6
10	Mancia G. (2020)	57.9	19.1	30.1	10.4	-	-	5.0	17.4
11	Mehra MR. (2020)	26.3	14.3	11.3	2.5	-	-	-	-
12	Meng J. (2020)	100	Total: 14.3 ACEI/ARB group: 11.8 Non-ACEI/ARB group: 16.0	Total: 19.0 ACEI/ARB group: 11.8 Non-ACEI/ARB group: 24.0	-	-	-	-	Total: 4.8 ACEI/ARB group: 0 Non-ACEI/ARB group: 8.0
13	Peng Y. (2020)	82.1	20.5	55.4	-	-	0	0	-
14	Rentsch CT. (2020)	72.3	44.4	27.9	15.4	-	10.3	19.0	14.2
15	Reynolds HR. (2020)	43.7	- ^a	- ^a	-	-	-	-	-
16	Tedeschi S. (2020)	100	23.8	42.1	15.8	-	-	-	-
17	Yan H. (2020)	(22.5) ^a	(9.8) ^a	(2.6) ^{a,b}	-	(2.6) ^{a,b}	(5.6) ^a	-	(1.8) ^a
18	Yang G. (2020)	100 (50.2)	30.2 (21.9) ACEI/ARB group: 30.2 Non-ACEI/ARB group: 30.1	18.3 (14.0) ACEI/ARB group: 16.3 Non-ACEI/ARB group: 19.3	4.7 (4.6) ACEI/ARB group: 7.0 Non-ACEI/ARB group: 3.6	7.9 (6.0) ACEI/ARB group: 9.3 Non-ACEI/ARB group: 7.2	6.3 (5.2) ACEI/ARB group: 7.0 Non-ACEI/ARB group: 6.1	2.4 (1.6) ACEI/ARB group: 0 Non-ACEI/ARB group: 3.6	-
19	Zeng Z. (2020)	100 (27.4)	30.7 (15.3)	21.3 (11.3)	9.3 (5.5)	14.7 (8.0)	4.0 (3.6)	5.3 (1.8)	2.7 (2.9)
20	Zhang P. (2020)	100	21.3 ACEI/ARB group: 23.4 Non-ACEI/ARB group: 20.9	11.7 ACEI/ARB group: 15.4 Non-ACEI/ARB group: 10.9	0.5 ACEI/ARB group: 0.5 Non-ACEI/ARB group: 0.5	3.6 ACEI/ARB group: 2.7 Non-ACEI/ARB group: 3.8	1.9 ACEI/ARB group: 2.1 Non-ACEI/ARB group: 1.8	3.1 ACEI/ARB group: 3.7 Non-ACEI/ARB group: 3.0	0

ACEI: angiotensin converting enzyme inhibitor, ARB: angiotensin II receptor antagonist

Some studies evaluated the association between ACEI/ARB use and severe disease or mortality only in the subgroup patients with hypertension. If the information is available, we described the information of hypertensive patients first, and then the information of all patients in the bracket.

^a Only the values of the whole patient cohort were available; The values of the subjects analyzed in the study were not presented.

^b Cardiovascular and cerebrovascular disease were reported as a combined value.